🇺🇸

US SEC Filing Intelligence

· daily

S&P 500 Consumer Discretionary Sector SEC Filings — July 21, 2026

All four filings originate from General Motors and its captive finance arm, GM Financial, making this a single-company deep dive rather than a broad sector overview. The overarching theme is a tale of two narratives: GM's operational strength (record EBIT-adjusted margins, raised full-year guidance, robust buyback activity) versus mounting credit stress in its financing unit (rising delinquencies, higher loan loss provisions, declining net income). Period-over-period comparisons reveal a 1.9% YoY revenue growth at the parent level, but net income attributable to stockholders plunged 31.1% YoY due to higher adjustments and tax expenses. GM Financial's net income fell 15-16% YoY, with the allowance for loan losses increasing 5.2% since year-end 2025, signaling deteriorating credit quality. The most critical development is the divergence between GM's raised EBIT-adjusted guidance ($14-16B) and the weakening consumer credit picture at GM Financial, which could pressure future earnings. No insider trading activity was reported in any filing, removing a key sentiment gauge. The portfolio-level pattern is a classic 'auto cycle tension' between strong manufacturing margins and rising consumer credit risk.

2 high priority 2 medium 4 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — July 21, 2026

The S&P 500 Healthcare sector shows a bifurcated landscape in Q2 2026: large-cap medical device and life sciences companies like Intuitive Surgical and Danaher are delivering strong operational performance, while insider activity at Johnson & Johnson raises concerns. Intuitive Surgical posted an 18.5% YoY revenue surge and 30.7% operating income growth, signaling robust demand for robotic surgery systems. Danaher reported a 60% YoY net earnings jump and raised full-year EPS guidance, though its Q3 core revenue guidance of 2.0%-3.0% suggests a potential deceleration from Q2's 3.0% actual. Eli Lilly's director stock awards are routine and non-material, while J&J's EVP sold $5.79M in stock after exercising options, a notable insider divestment. Cigna Investments' 13F shows a $485.8M portfolio heavily weighted toward tech giants, reflecting a cautious healthcare sector allocation. Key themes include margin expansion (Intuitive Surgical +150 bps gross margin), aggressive capital deployment (Intuitive's $1.44B buybacks vs $181M last year), and mixed forward guidance across the subsector.

7 high priority 2 medium 9 total filings
· daily

US Earnings Financial Results SEC Filings — July 21, 2026

The 20 filings for the period ending June 30, 2026, reveal a market characterized by divergent performance, with robust revenue growth in technology and industrial sectors (Intuitive Surgical +18.5%, Calix +24%, Danaher +57% net earnings) offset by significant margin compression and earnings declines in financial and consumer-facing companies (GM -31% net income, GPC -10.7%, Equifax -3.9% net income despite revenue growth). A dominant theme is aggressive capital allocation through share repurchases, with Intuitive Surgical ($1.44B), MSCI ($583M), and Marsh & McLennan ($1.51B) deploying substantial cash, often at the expense of balance sheet strength. Insider trading activity is notably absent across the filings, limiting one key signal source. The most critical developments include KKR Real Estate Finance Trust's widening net loss and dividend cut, Danaher's $9.8B acquisition, and the continued cash burn at pre-revenue companies like Tribal Rides and Conectisys Corp. Portfolio-level patterns indicate a bifurcation between companies successfully navigating cost pressures (3M, Danaher) and those facing rising expenses and credit losses (GM Financial, KKR).

20 high priority 20 total filings
· daily

US Executive Compensation Proxy SEC Filings — July 21, 2026

The six DEF 14A filings reveal a mixed governance landscape, with two companies undergoing significant structural transitions. StepStone Group Inc. is transitioning from a controlled to a non-controlled company post-Sunset, requiring board independence changes by September 2026. Eagle Nuclear Energy Corp. faces a contested board election with three nominees for two seats, creating potential governance instability. Sunbelt Rentals and Co-Diagnostics show stable, routine governance with no material financial or compensation changes. AB CarVal and Embrace Change Acquisition Corp. are special-purpose vehicles with minimal executive compensation disclosures, offering limited actionable insights. No period-over-period financial trends, insider trading, or forward-looking guidance were disclosed across these filings, limiting quantitative synthesis. The key theme is governance risk and transition, with Eagle Nuclear's contested election being the highest materiality event.

6 high priority 6 total filings
· daily

US IPO Pipeline SEC S-1 Filings — July 21, 2026

The IPO pipeline on July 21, 2026, reveals a stark contrast between a pre-revenue energy technology company attempting to go public and a clinical-stage biotech filing a registration for a potential reverse merger after a catastrophic regulatory setback. HNO International, Inc. is pursuing an IPO with zero revenue and mounting losses, relying on dilutive equity purchase agreements for survival, which signals a low-quality offering that may struggle to attract institutional demand. Passage BIO, Inc. is effectively filing a 'for sale' sign after its lead drug candidate PBFT02 was dealt a fatal blow by the FDA, triggering a 46% single-day stock collapse and a failed strategic review process where zero of three interested parties made an offer. The aggregate period-over-period data shows no revenue growth across either company (both have zero or de minimis revenue), while insider activity is absent from both filings, suggesting a lack of management conviction. The most critical development is Passage BIO's failed outreach to 148 counterparties, which strongly implies the asset has limited to no value and the S-4 is a precursor to a distressed merger or liquidation. The portfolio-level theme is a 'flight to quality' in the IPO market, where only companies with proven revenue and clear paths to profitability can successfully list, while speculative and pre-revenue companies face severe capital access constraints.

2 high priority 2 total filings
· daily

US SEC Trading Suspension Halt Orders — July 21, 2026

The three filings from July 21, 2026, reveal a concentrated wave of Nasdaq compliance and delisting actions affecting small-cap and micro-cap issuers, signaling heightened regulatory scrutiny on corporate governance, minimum bid price, and foreign issuer disclosures. Notably, two of the three companies face material threats to their listing status, with CN Healthy Food Tech Group Corp. receiving a direct delisting determination tied to CSRC review disclosures, while Cypherpunk Technologies Inc. is in a 180-day cure period for sub-$1.00 bid price non-compliance. Origin Investment Corp I quickly remedied its audit committee deficiency, demonstrating that governance gaps can be resolved swiftly. The aggregate data shows zero insider trading activity across all filings, suggesting management teams are not signaling conviction through personal transactions. No forward-looking guidance, capital allocation changes, or period-over-period financial comparisons were available in these event-driven 8-Ks, limiting trend analysis but amplifying the binary nature of the regulatory risks. The most critical development is CN Healthy Food Tech's July 23 appeal deadline, which will determine whether a full delisting and trading halt extension occurs, with material implications for shareholders of UCFI and UCFIW. The portfolio-level pattern is a clear uptick in Nasdaq enforcement actions against companies with governance gaps, low-priced stocks, and China-based operations facing CSRC scrutiny, creating both risk and potential catalyst-driven opportunities for active traders.

3 high priority 3 total filings
· daily

US Executive Officer Management Changes SEC — July 21, 2026

The July 21, 2026, batch of 29 filings reveals a significant wave of board and C-suite transitions across US-listed companies, with a notable concentration in the technology, energy, and financial sectors. While most changes are routine governance moves, several carry high materiality, including a CEO succession at Twenty One Capital tied to a strategic pivot away from a business combination, a CFO appointment at Upland Software from a distressed turnaround background, and a CMO departure at Polaryx Therapeutics that the company claims will not impact clinical timelines. Period-over-period comparisons were sparse in these event-driven filings, but insider activity and forward-looking statements provide actionable intelligence: the CEO of Ferrellgas extended her contract signaling stability, while Jet.AI's board decision to avoid diluting shareholders by not accelerating PSU vesting is a clear positive for existing holders. A key theme is the separation of Chairman and CEO roles at Jerash Holdings to strengthen governance, and the use of stock-based compensation at Ecominas Corp. and Aware, Inc. to align management incentives. The most critical development is the D&O insurance lapse at ClimateRock that triggered a director resignation, a rare governance red flag that warrants monitoring for similar issues at other small-cap SPACs.

29 high priority 29 total filings
· daily

US Corporate Board Director Changes SEC Filings — July 21, 2026

This digest of 29 USA Board Room Changes filings reveals a period of significant governance evolution, with a notable focus on financial expertise and strategic realignment. Key themes include the appointment of seasoned CFOs and financial leaders to boards (e.g., ExlService, MSA Safety, Blink Charging), a trend toward separating CEO and Chairman roles for improved governance (Jerash Holdings), and several C-suite departures signaling strategic pivots (Kemper Auto, Marriott Vacations). While most changes are routine, several carry high materiality, such as the CEO transition at Twenty One Capital and the CFO appointment at Upland Software, which are tied to specific strategic catalysts. The data shows a clear pattern of companies prioritizing financial discipline and operational efficiency, as evidenced by the appointment of directors with deep restructuring and capital allocation experience. The period-over-period comparisons, though limited in these filings, are supplemented by forward-looking statements and scheduled events that create a clear catalyst calendar for the next 30-60 days.

29 high priority 29 total filings
· daily

US Merger & Acquisition SEC Filings — July 21, 2026

The 18 filings reveal a bifurcated M&A landscape: SPAC activity is surging with three new IPOs (Samos Energy, Jones Ventures, AMR Resources) totaling $680 million in gross proceeds, alongside active deal financing (Aeon, Horizon Space) and advisory engagements (T-REX). However, this is tempered by notable failures—FACT II terminated its $175 million aerospace deal, and Vicarious Surgical is liquidating with zero expected recovery for stockholders. Operating company M&A shows mixed signals: Starco Brands' accretive acquisition of Custom Bakehouse ($20M revenue add) contrasts with Innovative Solutions' 1.5x revenue purchase of Aydin Displays, while Northpointe Bancshares' organic growth (MPP portfolio +36% YoY) is offset by margin compression (-11 bps YoY). Insider activity is sparse but negative, with Vicarious Surgical's entire board resigning and Flag Ship's auditor change flagged by material weaknesses. The overarching theme is capital rotation: SPACs are raising record sums but facing execution risk, while private equity take-privates (KORE Group) and targeted acquisitions signal selective value creation. No period-over-period comparisons were available for most filings, limiting trend analysis, but the data highlights a market favoring disciplined buyers over speculative SPACs.

18 high priority 18 total filings
· monthly

US Pre-Market SEC Filings Roundup — July 21, 2026

Overnight SEC filings reveal a mixed but cautious tone ahead of today's open, with a notable cluster of insider selling at high materiality levels. SharkNinja's CEO sold $38.8M in stock under a 10b5-1 plan, while Madrigal Pharmaceuticals' CEO exercised and sold options worth $372K, both generating bearish signals. The most critical development is an activist filing at Phunware, where Goldenwise Capital disclosed a 6.9% stake, publicly criticized governance, and threatened a proxy contest—the highest materiality event of the session. In the financial sector, Northfield Bancorp saw a wave of insider dispositions to the issuer, including the CEO returning 464K shares, suggesting a capital return event. On the positive side, Fulcrum Therapeutics saw a 10% owner buy $594K worth of stock, a bullish insider signal. Period-over-period data was limited in these filings, but the concentration of insider selling in biotech and consumer goods, combined with activist pressure at Phunware and a dilutive financing at VisionWave, points to a cautious market tone with select activist and insider-buying opportunities.

43 high priority 7 medium 50 total filings
· daily

VA Healthcare & Services Contracts — July 20, 2026

The single contract analyzed, a $190 million firm-fixed-price delivery order from the Department of Veterans Affairs to OptumServe Health Services (UnitedHealth Group subsidiary), represents a purely civilian healthcare services award with no defense exposure. The contract, fully competed and 92.4% executed, signals strong cash flow realization and competitive positioning for OptumServe in the stable VA disability examination market. However, the absence of option periods and the contract's completion in 2021 create recompetition risk. The key watch item is the timing of the next VA Region 2 disability exam solicitation, as this contract is fully mature and no longer generating new revenue.

1 total filings
· daily

New Federal Contractors — July 20, 2026

The three contracts analyzed total $5.2 billion in obligations, all from civilian agencies (0% defense-related), signaling a strong but narrow civilian procurement theme. The dominant signal is Leidos Biomedical Research Inc.'s $4.81B award from HHS, a high-conviction bullish event that dwarfs the other two contracts combined. However, the HHS contract lacks critical details on pricing, competition, and revenue recognition, creating execution risk. The other two contracts—Cardinal Intellectual Property's $191.9M USPTO award and OptumServe's $190M VA order—are neutral, with the latter nearly fully executed. Key risk: the $0 outlay on the 13-year Cardinal contract suggests delayed revenue recognition, while the Leidos award's 2008 start date raises questions about current relevance.

3 total filings
· daily

Significant Contract Modifications ($10M+) — July 20, 2026

The three contracts analyzed total $5.2 billion, all from civilian agencies, with no defense-related awards. The dominant theme is a massive $4.81 billion award to Leidos Biomedical Research from the Department of Health and Human Services, representing the highest-conviction bullish signal despite being a modification to an existing contract. The other two contracts—Cardinal Intellectual Property ($192 million) and OptumServe Health Services ($190 million)—are neutral, with the former carrying execution risk due to zero outlayed funds and the latter nearing completion. Key risks include budget uncertainty from the ongoing Continuing Resolution and the potential for protest or recompetition on the OptumServe contract.

3 total filings
· daily

Contract Deobligations Alert — July 20, 2026

The three contracts analyzed total $5.195 billion, all from civilian agencies with no defense exposure, signaling a significant shift in government spending toward health and intellectual property services. The dominant theme is a massive $4.81 billion Leidos Biomedical Research contract from HHS, which is the highest-conviction signal but lacks pricing and competition details, creating uncertainty. A $191.9 million Cardinal Intellectual Property contract from the USPTO offers long-term revenue visibility but has zero outlayed funds, raising execution risk. The $190 million OptumServe VA contract is nearly fully executed, indicating strong cash flow realization. Key risks include the lack of defense contracts, which may underweight sector exposure, and the need to monitor the Leidos contract's activation and Cardinal's revenue recognition.

3 total filings
· daily

Contract Option Exercises — July 20, 2026

This digest covers $5.2 billion in contract option exercises, all from civilian agencies, with zero defense-related awards. The dominant signal is a massive $4.81B sole-source award to **Leidos Biomedical Research** from the Department of Health and Human Services, representing 93% of total obligation and carrying the highest conviction (bullish, 7/10). This dwarfs two smaller, competitively-won civilian contracts to **Cardinal Intellectual Property** ($192M, USPTO) and **OptumServe** ($190M, VA). The key risk is the lack of defense exposure in a period typically sensitive to Continuing Resolution dynamics, while the key watch item is the activation status of the Leidos Biomedical contract, given its size and potential for revenue recognition delays.

3 total filings
· daily

All HHS Contracts — July 20, 2026

This digest covers a single, massive $4.81B contract awarded to Leidos Biomedical Research Inc. by the Department of Health and Human Services (HHS), a civilian agency. Despite the 'defense contract' label in the raw data, the award is entirely civilian in nature, with zero defense-related contracts in the stream. The dominant theme is a high-conviction, sole-source or long-standing relationship between HHS and Leidos Biomedical, signaling a durable revenue stream for the company. Key risks include the lack of pricing and competition details, which could imply cost-plus risk or protest vulnerability. Investors should monitor this as a potential multi-year program anchor for Leidos' government services segment.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — July 20, 2026

This digest covers three civilian agency contracts totaling $5.2 billion, with zero defense-related awards, signaling a heavy tilt toward health and administrative services. The dominant theme is a massive $4.81B award to Leidos Biomedical Research from HHS, which accounts for 93% of total obligation and represents the highest-conviction signal despite limited data. Neutral signals from Cardinal Intellectual Property ($192M, USPTO) and OptumServe ($190M, VA) indicate competitive wins with execution risks, but the Leidos award alone drives a bullish sector view on biomedical research outsourcing. Key risks include the lack of outlayed funds on the Cardinal contract and the near-complete execution of the OptumServe order, which leaves no near-term revenue runway.

3 total filings
· daily

High-Value Federal Grants ($5M+) — July 20, 2026

This digest covers three high-value federal contracts totaling $5.2 billion, all civilian (0% defense), with a dominant $4.8 billion award to Leidos Biomedical Research Inc. from HHS. The highest-conviction signal is the Leidos award, which is classified as a defense contract from a civilian agency, suggesting potential misclassification or dual-use biomedical research with defense applications. A key risk is the $0 outlayed amount on the $192 million Cardinal Intellectual Property contract, indicating possible delays or non-activation, while the $190 million OptumServe VA contract is nearly fully executed, signaling strong cash flow realization but limited future visibility.

3 total filings
· daily

General Federal Contracts — July 20, 2026

This digest covers three civilian contracts totaling $5.2 billion, with zero defense-related awards, underscoring a heavy tilt toward health and intellectual property services. The dominant signal is Leidos Biomedical Research's $4.81 billion award from HHS, which accounts for 93% of total obligation and carries a bullish 7/10 signal strength, though its defense classification and lack of pricing or competition details introduce uncertainty. Cardinal Intellectual Property's $192 million USPTO contract offers long-term revenue visibility but has zero outlays to date, raising execution risk. OptumServe's $190 million VA award is nearly fully executed, confirming strong performance but signaling recompetition risk. The key watch item is the activation and outlay trajectory of the Leidos contract, given its outsized weight.

3 total filings
· daily

Nasdaq 100 Stocks SEC Filings — July 20, 2026

The single filing from Strategy Inc (STRD) for the week of July 13-19, 2026, reveals a notable pause in the company's aggressive bitcoin acquisition strategy, with no BTC purchases and no preferred stock sales for the first time in recent weeks. The company raised $263.5 million via its ATM program but held the proceeds in its USD Reserve ($3.225 billion), signaling a potential shift to a more cautious capital allocation posture. Despite the pause, the company's massive BTC holdings (843,775 BTC at an average cost of $75,476) and the $21.0 billion MSTR Increase authorization provide a significant future catalyst for further accumulation. The lack of share repurchases under the buyback program suggests management prioritizes BTC acquisition over shareholder returns. This filing, while neutral in sentiment, highlights a critical inflection point: Strategy Inc is accumulating dry powder, which could precede a major BTC purchase or signal a strategic reassessment. The broader NASDAQ-100 context is quiet, but this single data point is highly material for crypto-exposed investors.

1 medium 1 total filings